^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
Source:
Title:

CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients

Published date:
11/04/2021
Excerpt:
Five patients, 3 HL and 2 NHL, were enrolled on a phase Ib/II study and received 1x108 CD30.CAR-T cells/m2....One patient with ALK+ ALCL had symptoms compatible with CRS and macrophage activation syndrome (maximum ferritin >100,000 ng/mL and CRP 39.7 mg/L), which were ultimately determined to be secondary to progressive disease...One patient with ALK negative ALCL remains in CR while the patient with ALK+ ALCL had rapid relapse.
DOI:
10.1182/blood-2021-153968